PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 4 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 5 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 1 year 5 months ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 5 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 5 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
BRIEF published on 06/19/2024 at 13:05, 1 year 5 months ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 5 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 5 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
BRIEF published on 06/18/2024 at 13:05, 1 year 5 months ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 5 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 12/05/2025 at 02:35, 8 hours 48 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 10 hours 23 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 18 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 23 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 11:08, 14 minutes ago Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 12/05/2025 at 10:30, 53 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 8 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 43 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 08:45, 2 hours 38 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 2 hours 38 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 2 hours 41 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 17 hours 8 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 17 hours 23 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
